Ann Michelle Cunningham - Mar 1, 2022 Form 4 Insider Report for VistaGen Therapeutics, Inc. (VTGN)

Role
CHIEF COMMERCIAL OFFICER, Director
Signature
/s/ Jerrold D. Dotson, Attorney-in-Fact
Stock symbol
VTGN
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 03:15 PM
Next filing
Mar 6, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTGN Stock Option (Right to Buy) Award $0 +150K $0.00 150K Mar 1, 2022 Common Stock 150K $1.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan. Twenty-five percent (25%) of the total number of shares vest immediately on March 1, 2022 (the "Vesting Start Date") and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested two (2) years after the Vesting Start Date.